The 2023 FDA New Drug Report cites 84% ​​first cycle approval – what about generic drugs?

 

 

In the FDA report, ``Advancing Health Through Innovation: Approving New Drug Therapies in 2023,'' the FDA describes its progress in approving new drugs (``for treatments not previously approved in the United States''). and says: We highly recommend reading the entire report as there are many interesting statistics. I think the most interesting and relevant metric is that of the 55 new drug therapies approved in 2023, 84%, or 49, were approved in the first review cycle.

This is not an easy task as these new medicines require the most complex approvals. This is because authorities are dealing with medicines that have different mechanisms of action, are new chemicals, or treat diseases for which no other treatments are available. Nevertheless, the FDA was able to approve 84% in the first testing cycle. CDER explains the factors that led to this success in the report's conclusion:

“The review of drug applications, whether for new drugs or additional marketing authorizations, is a collaborative and well-coordinated process involving scientific, regulatory, and policy experts from across CDER and sometimes from other government agencies. From the department of. For each application, safety and efficacy data are very carefully and carefully analyzed, including a benefit-risk analysis that takes into account the severity of the disease and symptoms, currently available treatment options, and the targeted patient population. If a treatment meets the approval criteria, it is necessary to agree on indications, labeling, safety, etc and to know about FDA compliance consultant.

We frequently consult with external scientific experts, patients and patient advocates, industry representatives, academics, and other community members involved in drug development and review. Each of these parties has unique expertise and perspectives, and we take their perspectives into account. We take regulatory decisions seriously because we know our decisions impact the health and well-being of patients and consumers across the country. ”